Coordinating stability, CPV, and comparability data for PAS submissions Coordinating Stability, CPV, and Comparability Data for PAS Submissions Context In the ever-evolving landscape of pharmaceutical and biotech development, the ability to navigate post-approval changes (PAC) is crucial for maintaining compliance with regulatory requirements. These changes, which may include modifications related to manufacturing processes, formulation, or specifications, are governed by stringent guidelines set forth by regulatory authorities such as the FDA, EMA, and MHRA. The submission of a Post-Approval Supplement (PAS) is one of the primary pathways to manage these changes while ensuring that product quality, safety, and efficacy are upheld…

Governance models for change control decisions with CMC implications Governance models for change control decisions with CMC implications In the highly regulated pharmaceutical and biotechnology sectors, effective management of post-approval changes (PACs) is crucial. This comprehensive guide delves into the regulations, guidelines, and agency expectations surrounding PACs, specifically under the categories of Post Approval Supplement (PAS), Changes Being Effected in 30 days (CBE-30), and Changes Being Effected Immediately (CBE-0). Understanding how to navigate these paths ensures compliance and helps avoid common pitfalls in the regulatory process. Context Change control in the context of Chemistry, Manufacturing, and Controls (CMC) is essential…

Common FDA Questions on PAS and CBE Submissions and How to Avoid Them Common FDA Questions on PAS and CBE Submissions and How to Avoid Them In the world of pharmaceutical and biotechnology product development, navigating the complexities of regulatory requirements for post-approval changes (PAC) is pivotal for ensuring compliance and maintaining product quality. This article serves as a comprehensive regulatory explainer manual for Kharma and regulatory professionals, focusing on the common questions posed by the FDA regarding Post-Approval Supplements (PAS), Changes Being Effected in 30 Days (CBE-30), and Changes Being Effected Immediately (CBE-0) submissions. We will delve into relevant…

Digital tools to track global post approval change commitments and status Digital tools to track global post approval change commitments and status The evolving landscape of pharmaceutical regulation necessitates a comprehensive understanding of post-approval changes (PAC), including the classifications of Post-Approval Supplements (PAS), Changes Being Effected in 30 Days (CBE-30), and Changes Being Effected Immediately (CBE-0). Regulatory professionals must adequately track, manage, and justify these changes across multiple jurisdictions, including the US, EU, and UK. This article serves as an exhaustive regulatory explainer manual to navigate the complexities of these processes and the expectations set forth by agencies such as…

Lifecycle planning to minimise the number of PAS filings over time Lifecycle planning to minimise the number of PAS filings over time Context In the pharmaceutical and biotechnology industries, regulatory affairs (RA) serves as the bridge between the company and the regulatory authorities, ensuring that products meet necessary requirements for safety, efficacy, and quality. A crucial aspect of RA is the management of post-approval changes (PAC), which includes the implementation of modifications to manufacturing processes, facilities, and controls after a product has been approved. This article focuses on understanding the various types of post-approval submissions, specifically the Difference Between Post-Approval…

Audit readiness of documentation supporting post approval change history Audit Readiness of Documentation Supporting Post Approval Change History Context In the pharmaceutical and biotech industries, Post Approval Changes (PAC) are modifications made to an approved drug product after it has received an authorization from the relevant regulatory authority. These changes can occur in various aspects, including manufacturing processes, quality control procedures, and labeling. Compliance with regulatory expectations for documenting and classifying these changes is critical for maintaining product integrity and regulatory approval. This article aims to provide a clear regulatory affairs explainer manual on the documentation and submission requirements associated…

CMC strategies for tech transfer and site change comparability CMC Strategies for Tech Transfer and Site Change Comparability The effective management of Chemistry, Manufacturing, and Controls (CMC) processes is critical in ensuring the continuous supply and quality of pharmaceutical products. This regulatory explainer manual delves into the essential components of CMC tech transfer comparability, site changes, bridging studies, and the associated regulatory expectations in the US, UK, and EU. Context CMC tech transfer is the process of transferring analytical methods, manufacturing processes, and control strategies from one site to another. This process is critical during the lifecycle of a product,…

Designing comparability protocols for site transfers and scale changes Designing Comparability Protocols for Site Transfers and Scale Changes Regulatory Affairs (RA) professionals play a pivotal role in ensuring that pharmaceutical and biotech products maintain their quality and efficacy throughout the product lifecycle. In the context of Chemistry, Manufacturing, and Controls (CMC) lifecycle management, tech transfer and site changes pose significant challenges. This article provides an in-depth regulatory explainer on the design and implementation of comparability protocols for site transfers and scale changes. We will explore the regulatory framework, key guidelines, agency expectations, and common deficiencies to avoid. Regulatory Context The…

Tech transfer playbook from sending to receiving manufacturing sites Tech Transfer Playbook: From Sending to Receiving Manufacturing Sites Context of CMC Tech Transfer Comparability In the pharmaceutical and biotech sectors, CMC (Chemistry, Manufacturing, and Controls) tech transfer is a critical process that involves the transfer of manufacturing processes, product specifications, and testing protocols from one location to another. This transition from a sending site to a receiving site requires thorough documentation, risk assessment, and demonstration of comparability to ensure that the product’s quality, safety, and efficacy are maintained. The regulatory landscape in the US, UK, and EU mandates that any…

Using Risk Assessments to Focus CMC Work During Tech Transfers Using Risk Assessments to Focus CMC Work During Tech Transfers The complex and multifaceted nature of pharmaceutical product development necessitates a comprehensive understanding of regulatory affairs, especially when it comes to Chemistry, Manufacturing, and Controls (CMC) during technology transfers. This article serves as an exhaustive manual that outlines the fundamental aspects and regulatory expectations applicable to CMC tech transfer comparability, site changes, bridging studies, and risk assessments. Regulatory Affairs Context for CMC Tech Transfer Comparability In the realm of CMC, tech transfer represents the process of transferring information, materials, and…